ABBOTT INDIA LIMITED

The TRANSCEND study evaluates Abbott's DBS system for treatment-resistant depression (TRD), granted FDA Breakthrough Device designation. A multi-centered, double-blind, randomized, sham-controlled trial plans to enroll 100 participants, aged 22-70, who have failed at least 4 antidepressant treatments. Success is measured by improvements in Montgomery-Asberg Depression Rating Scale (MADRS) scores after 12 months, with all participants having DBS turned on for an additional 2 years. Challenges include patient selection, target brain circuit identification, and maintaining response over time.

Abbott starts a pivotal clinical trial, TRANSCEND, to assess its deep brain stimulation (DBS) system for treatment-resistant depression (TRD), a major depressive disorder form. The FDA granted Abbott Breakthrough Device designation for exploring DBS use in TRD, aiming to improve lives of the approximately 2.8 million Americans diagnosed with TRD annually.

Abbott initiated a pivotal clinical trial, TRANSCEND, to evaluate deep brain stimulation (DBS) for treatment-resistant depression (TRD). The FDA granted Abbott Breakthrough Device designation for DBS in TRD, aiming to improve lives of those with the condition. Approximately 2.8 million Americans annually are diagnosed with TRD, a form of major depressive disorder unresponsive to multiple treatments. DBS, working like a pacemaker, sends electrical pulses to the brain to relieve symptoms, with previous studies showing at least 50% improvement in depression symptoms for three out of four people over two to eight years.